SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

CYTK

Cytokinetics, Incorporated
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The offering overhang may pressure CYTK shares in the short term as the 11.3 million new shares enter the market. Monitor for price stabilization and any updates on use of proceeds. Historically, similar-sized offerings for biotechs can lead to 5-10% declines within a week.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$76.91
T+0 close · May 8, 2026 · via day close
Latest settled
+2.21%
T+60 · $78.61
Vs SPY
−2.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $76.91entry
  2. T+1 · 6mo ago −3.06%α −3.29% · $74.56
  3. T+5 · 6mo ago +2.25%α +0.79% · $78.64
  4. T+20 · 5mo ago −7.06%α −7.08% · $71.48
  5. T+60 · 3mo ago +2.21%α −2.63% · $78.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics closed an underwritten public offering of 11.3 million shares at $71.00 per share, raising approximately $805 million in gross proceeds. The offering represents dilution of about 8.7% of the pre-offering market capitalization, which may pressure the stock in the near term as the additional shares enter the market.

Key Financial Metrics

Deal Value
$805.0M

Key Facts

  • Offering of 11,338,028 shares at $71.00 per share
  • Gross proceeds of approximately $805 million
  • Full exercise of underwriters' option to purchase additional shares
  • Closing of offering announced on May 08, 2026

Financial Impact

Gross proceeds of $805 million, representing dilution of approximately 8.7% of pre-offering market capitalization

dilutioncash

Risk Factors

  • Dilutive effect of 8.7% increase in share count
  • Potential short-term selling pressure from offering participants
  • Uncertainty about use of proceeds

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291210

Track record

46 reports on CYTK

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026